Short answer
Assembly Biosciences Inc (ASMB) filed its fiscal 2010 10-K annual report with the SEC on Apr 13, 2011.
- Top risk flagged: FDA approval risk: VEN 307 patent application faced a lack-of-inventiveness rejection after the August 31, 2010 appeal decision
Assembly Biosciences Inc FY2010 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Development-stage specialty pharmaceutical model, advancing licensed late-stage gastrointestinal drugs through regulatory approval
- Post-IPO emphasis on VEN 309 Phase III hemorrhoid program and VEN 307 anal-fissure development
- Initial public offering in December 2010 enabled renewed development after delays caused by insufficient financial resources
- Five employees hired after the IPO, plus three contracted individuals or entities for the planned VEN 309 Phase III trial
- Portfolio targets over 23 million U.S. adults across hemorrhoids, anal fissures and fecal incontinence without FDA-approved prescription treatments
Management Discussion & Analysis
- No product revenue since inception; accumulated development-stage deficit $33,184,354 at December 31, 2010
- Net loss not disclosed; R&D expense $1,850,667 vs $2,942,992, down 37%
- Highest development spending: VEN 307 at $1,309,501; lowest: Other at $161,928
- Operating cash use $5,252,826; financing cash $19,704,194; IPO net proceeds approximately $15.7 million
- Cash expected through third quarter 2012; Phase III trials planned, additional funding required, FDA and financing risks remaining
Risk Factors
- FDA approval risk: VEN 307 patent application faced a lack-of-inventiveness rejection after the August 31, 2010 appeal decision
- Funding runway: Existing cash projected to fund operations only into the third quarter of 2012
- Manufacturing dependency: Product candidates manufactured entirely by commercial third parties subject to FDA cGMP compliance
- Competitive threat: ProStrakan developing topical nitroglycerin for anal fissures
- Leverage and concentration: $1,573,000 owed to Paramount Credit Partners, an affiliate of largest stockholder Dr. Rosenwald
Generated from the filing text; verify against the original. How to read a 10-K
Other Assembly Biosciences Inc annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.